Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation develops and markets therapies for rare cardiopulmonary and related diseases, with a pulmonary arterial hypertension franchise built around treprostinil products such as Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin and Orenitram. News commonly covers product sales, quarterly results, clinical data for pulmonary hypertension, idiopathic pulmonary fibrosis and interstitial lung disease, and updates on ralinepag and the TETON program.
The company also reports developments in manufactured-organ and transplant-support technologies, including EVLP, xenotransplantation, and Miromatrix Medical programs such as miroliverELAP and mirokidney. Governance updates, board composition, share repurchase activity and its status as a public benefit corporation are recurring corporate themes.
United Therapeutics Corporation (Nasdaq: UTHR) is set to present data from the INCREASE study on Tyvaso® (treprostinil) Inhalation Solution for pulmonary hypertension associated with interstitial lung disease at the American Thoracic Society's session on June 24, 2020. The phase III trial showed a significant increase in six-minute walk distance by 21 meters compared to placebo (p=0.0043) after 16 weeks and improvements in secondary endpoints, including biomarkers. The company has submitted a supplemental New Drug Application to the FDA to update the Tyvaso label with these findings.